GlassScriptPhysician profile
Alvin V Tenchavez
NPI 1225023211
$9,633.39
in general payments reported to CMS, 2019-2025
62 companies · $829 in 2025
The $829 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $1,463 · 2021: $1,348 · 2022: $1,310 · 2023: $1,879 · 2024: $1,304 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,912 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,911.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,097.28 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,011.65 | 2019-2025 | Relistor, Xifaxan |
| Abbvie INC. | $980.94 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $775.01 | 2019-2025 | Farxiga, Breztri, Bevespi Aerosphere |
| Otsuka America Pharmaceutical, INC. | $701.68 | 2021-2025 | Rexulti |
| Amgen INC. | $609.89 | 2019-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $302.39 | 2019-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $297.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $263.20 | 2019-2025 | Spravato |
| Pfizer INC. | $259.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $250.63 | 2019-2023 | Belsomra, Verquvo |
| Allergan, INC. | $221.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $188.62 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $163.14 | 2019-2021 | |
| Lundbeck LLC | $154.43 | 2023-2025 | Rexulti, Vyepti |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Tenchavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.